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The growing health problems demand search and synthesis of
a new class of antimicrobial compounds which are effective
against pathogenic microorganisms, developing resistance to
the antibiotics used in the current regime (Koca et al., 2005).
The increasing resistance of human pathogens to current anti-
microbial agents is a serious medical problem. During the 20th
century, vaccines for bacterial toxins and many other common
acute viral infections were developed and made widely avail-
able. A number of different classes of antibacterial (Appelbaumand Hunter, 2000; Ball, 2000) and antifungal agents (Andriole,
1998) have been discovered. Since the discovery of several syn-
thetic and semi-synthetic antibacterial sulfa drugs, nitrofur-
anes, penicillins, cephalosporins, tetracyclines, macrolides,
oxazolidinones and antifungal agents such as ﬂuconazole,
ketoconazole and miconazole, including amphotericin B, there
has been much progress in this ﬁeld. Despite advances in anti-
bacterial and antifungal therapies, many problems remain to
be solved for most antimicrobial drugs available. The extensive
use of antibiotics has led to the appearance of multi-drug resis-
tant microbial pathogens (Frere, 1995).
As pyrimidine is a basic nucleus in DNA & RNA, it has
been found to be associated with diverse biological activities
(Ghoneim and Youssef, 1986). The synthesis of substituted
pyrimidine and many detailed reviews have appeared (Kenner
and Todd, 1957; Brown, 1962). Pyrimidine and its derivatives
are considered to be important for drugs and agricultural
chemicals. Pyrimidine derivatives possess several interesting
biological activities such as antimicrobial (Karale and Gill,
2002), antitumor (Reddy and Sarma Rama, 1993) and anti-
fungal activities (Shingare et al., 1999). Many Pyrimidine
Studies on synthesis of pyrimidine derivatives and their antimicrobial activity S485derivatives are used for thyroid drugs and leukemia. In view of
these reports, the present paper reports the synthesis of
2-(5-bromo-2-chloro-pyrimidin-4-ylsulfanyl)-4-methoxy-phenyl-
amine derivatives, 4a–i characterized by different spectral
studies. Antimicrobial activity of all the compounds was also
reported.2. Chemistry
2-(5-Bromo-2-chloro-pyrimidin-4-ylsulfanyl)-4-methoxy-phen-
ylamine derivatives, 4a–i were prepared by the method
summarized in Scheme 1. The target key intermediate, 2-(5-
bromo-2-chloro-pyrimidin-4-ylsulfanyl)-4-methoxy-phenylamine
(2) was synthesized according to the reported procedure
(Chang et al., 2009). Compound (2) was reacted with various
aromatic sulfonyl chlorides, 3a–i in MDC and the reaction
mass was stirred for 2 h at room temperature. The obtained so-
lid was ﬁltered and washed with ethanol. The residue 4a–i
yields 70–78%. These synthesized compounds were character-
ized by elemental analyses, FT-IR, 1H NMR and LC–MS
spectral studies. Antimicrobial activity was reported. The
chemical structures, physical data and purity of all the synthe-
sized compounds are given in Table 1.3. Experimental
3.1. Materials and equipments
All solvents and reagents were purchased from Merck
chemicals. Melting range was determined by Veego Melting
Point VMP III apparatus. Elemental analyses were recorded
on VarioMICRO superuser V1.3.2 Elementar. The FT-IR
spectra were recorded using KBr discs on FT-IR Jasco 4100
infrared spectrophotometer. 1H NMR spectra were recorded
on Bruker DRX -500 spectrometer at 400 MHz using
d6-DMSO as solvent and TMS as internal standard. Silica
gel column chromatography was performed using Merck
7734 silica gel (60–120 mesh) and Merck-made TLC plates.
3.2. General procedure for synthesis of 2-(5-bromo-2-chloro-
pyrimidin-4-ylsulfanyl)-4-methoxy-phenylamine derivatives 4a–i
A solution of 2-(5-bromo-2-chloropyrimidin-4-ylthio)-4-meth-
oxybenzenamine (2) (1.0 eq) in dry dichloromethane was taken
and cooled to 0–5 C in an ice bath. Triethylamine (3.0 eq) was
added to the cold reaction mixture and stirred for 10 min, then
different sulfonyl chlorides (3a–i) (1.0 eq) were added, the reac-
tion mixture was stirred at room temperature for 7–8 h. The
progress of the reaction was monitored by TLC. Upon com-
pletion, the solvent was removed under reduced pressure andN
N
Br
Cl S
O
NO2
N
N
Br
Cl S
O
HCl, 0 C, r.t
1 2
SnCl2 H2O
°
Schemeresidue was taken in water and extracted with ethyl acetate.
The organic layer was washed with 10% ammonium chloride
solution and ﬁnally water wash was given to organic layer
and dried with anhydrous sodium sulfate. The solvent was
evaporated to get a crude product which was puriﬁed by col-
umn chromatography over silica gel (60–120 mesh) using hex-
ane:ethyl acetate (8:2) as eluent.
3.2.1. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-2,4,6-trimethyl-
benzenesulfonamide (4a)
The general experimental procedure described above afforded
4a, and the product obtained from 2-(5-bromo-2-chloropyrim-
idin-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol)
and 2,4,6-trimethylbenzene-1-sulfonyl chloride (3a) (2.19 g,
0.01 mol). FT-IR (KBr, cm1) m: 3176 (N–H), 2924 (C–H),
1698 (C‚N), 1463 (C‚C), 1376 (C–N), 1151 (C–O), 722
(C–Cl), 521 (C–Br). 1H NMR (DMSO-d6, 400 MHz) d: 9.66
(s, 1H, Pyrimidine-H), 8.55 (s, 1H, Ar-H), 7.47 (d, 1H, Ar-
H), 7.14 (d, 1H, Ar-H), 7.03 (s, 1H, NH), 6.61 (s, 2H, Ar-
H), 3.71 (s, 3H, OCH3), 2.29–1.99 (s, 9H, CH3). MS (ESI)
m/z: 529.0. Anal. calcd. for C20H19BrClN3O3S2 (in %): C-
45.42, H-3.62, N-7.95. Found C-45.62, H-3.72, N-8.12.
3.2.2. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-4-chloro-benzenesulfonamide (4b)
The general experimental procedure described above afforded
4b, and the product obtained from 2-(5-bromo-2-chloropyrim-
idin-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol)
and 4-chlorobenzene-1-sulfonyl chloride (3b) (2.12 g,
0.01 mol). FT-IR (KBr, cm1) m: 3282 (N–H), 2924 (C–H),
1698 (C‚N), 1462 (C‚C), 1376 (C–N), 1166 (C–O), 722
(C–Cl), 627 (C–Br). 1H NMR (DMSO-d6, 400 MHz) d: 9.89
(s, 1H, Pyrimidine-H), 8.65(s, 1H, Ar-H), 7.57 (d, 2H,
Ar-H), 7.46 (d, 2H, Ar-H), 7.29 (d, 1H, Ar-H), 7.13 (d, 1H,
Ar-H), 7.11 (s, 1H, NH), 3.74 (s, 3H, OCH3). MS (ESI) m/z:
522.3 Anal. calcd. for C17H12BrCl2N3O3S2 (in %): C-39.17,
H-2.32, N-8.06. Found C-39.25, H-2.46, N-8.26.
3.2.3. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-4-methyl-benzenesulfonamide
(4c)
The general experimental procedure described above afforded
4c, and the product obtained from 2-(5-bromo-2-chloropyrim-
idin-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol)
and 4-methylbenzene-1-sulfonyl chloride (3c) (1.91 g,
0.01 mol). FT-IR (KBr, cm1) m: 3275 (N–H), 2925 (C–H),
1698 (C‚N), 1463 (C‚C), 1376 (C–N), 1165 (C–O), 722
(C–Cl), 561 (C–Br). 1H NMR (DMSO-d6, 400 MHz) d: 9.66
(s, 1H, Pyrimidine-H), 8.63 (s, 1H, Ar-H), 7.43 (d, 2H,
Ar-H), 7.26 (d, 2H, Ar-H), 7.15 (d, 1H, Ar-H), 7.10 (d, 1H,NH2
N
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Table 1 Chemical structure and physical data of 2-(5-bromo-2-chloro-pyrimidin-4-ylsulfanyl)-4-methoxy-phenylamine derivatives 4a–i.
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S488 C. Mallikarjunaswamy et al.Ar-H), 7.06 (s, 1H, NH), 3.72 (s, 3H, OCH3), 2.23 (s,
3H, CH3). MS (ESI) m/z: 501.1. Anal. calcd. for
C18H15BrClN3O3S2 (in %): C-43.17, H-3.02, N-8.39. Found
C-43.31, H-3.24, N-8.56.
3.2.4. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-benzene sulfonamide (4d)
The general experimental procedure described above afforded
4d, and the product obtained from 2-(5-bromo-2-chloropyrim-
idin-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol)
and benzene sulfonyl chloride (3d) (1.77 g, 1.2 mmol). FT-IR
(KBr, cm1) m: 3272 (N–H), 2924 (C–H), 1698 (C‚N), 1458
(C‚C), 1376 (C–N), 1165 (C–O), 721 (C–Cl), 577 (C–Br).
1H NMR (DMSO-d6, 400 MHz) d: 9.70 (s, 1H, Pyrimidine-
H), 8.61 (s, 1H, Ar-H), 7.57 (d, 2H, Ar-H), 7.45 (t, 3H, Ar-
H), 7.23 (d, 1H, Ar-H), 7.09 (d, 1H, Ar-H), 7.06 (s, 1H,
NH), 3.72 (s, 3H, OCH3). MS (ESI) m/z: 487.0. Anal. calcd.
for C17H13BrClN3O3S2 (in %): C-41.94, H-2.69, N-8.63.
Found C-42.11, H-2.84, N-8.76.
3.2.5. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-2-tri ﬂuoro methyl-benzene
sulfonamide (4e)
The general experimental procedure described above afforded
4e, and the product obtained from 2-(5-bromo-2-chloropyrim-
idin-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol)
and 2-triﬂuoromethyl-benzenesulfonyl chloride (3e) (2.44 g,
0.01 mol). FT-IR (KBr, cm1) m: 3271 (N–H), 2923 (C–H),
1697 (C‚N), 1461 (C‚C), 1372 (C–N), 1271 (C-F), 1164
(C–O), 721 (C–Cl), 562 (C–Br). 1H NMR (DMSO-d6,
400 MHz) d: 9.72 (s, 1H, Pyrimidine-H), 8.63 (s, 1H, Ar-H),
7.83–7.50 (d, 2H, Ar-H), 7.41 (t, 2H, Ar-H), 7.21 (d, 2H, Ar-
H), 7.01 (s, 1H, NH), 3.77 (s, 3H, OCH3). MS (ESI) m/z:
555.0. Anal. calcd. For C18H12BrClF3N3O3S2 (in %): C-
38.97, H-2.18, N-7.57. Found C-38.91, H-2.23, N-7.52.
3.2.6. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-4-tert-butyl-benzenesulfonamide
(4f)
The general experimental procedure described above afforded
4f, and the product obtained from 2-(5-bromo-2-chloropyrim-
idin-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol)
and 4-tert-butyl-benzenesulfonyl chloride (3f) (2.32 g,
0.01 mol). FT-IR (KBr, cm1) m: 3273 (N–H), 2924 (C–H),
1693 (C‚N), 1463 (C‚C), 1374 (C–N), 1161 (C–O), 723
(C–Cl), 565 (C–Br). 1H NMR (DMSO-d6, 400 MHz) d: 9.65
(s, 1H, Pyrimidine-H), 8.61 (s, 1H, Ar-H), 7.44 (d, 2H, Ar-
H), 7.27 (d, 2H, Ar-H), 7.16 (d, 1H, Ar-H), 7.13 (d, 1H, Ar-
H), 7.08 (s, 1H, NH), 3.76 (s, 3H, OCH3), 2.21 (s, 9H, CH3).
MS (ESI) m/z: 543.0. Anal. calcd. for C21H21BrClN3O3S2 (in
%): C- 46.46, H-3.90, N-7.74. Found C-46.49, H-3.96, N-7.77.
3.2.7. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-4-methyl-benzenesulfonamide
(4g)
The general experimental procedure described above afforded
4g, and the product obtained from 2-(5-bromo-2-chloropyrimi-
din-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol) and
4-methly-benzenesulfonyl chloride (3g) (1.14 g, 0.01 mol). FT-
IR (KBr, cm1) m: 3274 (N–H), 2922 (C–H), 1696 (C‚N),1465 (C‚C), 1371 (C–N), 1166 (C–O), 725 (C–Cl), 564 (C–
Br). 1H NMR (DMSO-d6, 400 MHz) d: 9.64 (s, 1H, Pyrimi-
dine-H), 8.63 (s, 1H, Ar-H), 7.43 (d, 2H, Ar-H), 7.06 (s, 1H,
NH), 3.72 (s, 3H, OCH3), 2.23 (s, 3H, CH3). MS (ESI) m/z:
425.0. Anal. calcd. for C12H11BrClN3O3S2 (in %): C-33.93, H-
2.61, N-9.89. Found C-33.99, H-2.66, N-9.86.
3.2.8. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-2,5-dichloro-
benzenesulfonamide (4h)
The general experimental procedure described above afforded
4h, and the product obtained from 2-(5-bromo-2-chloropyrim-
idin-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol)
and 2, 5-dichloro-benzenesulfonyl chloride (3h) (2.44 g,
0.01 mol). FT-IR (KBr, cm1) m: 3271 (N–H), 2924 (C–H),
1695 (C‚N), 1461 (C‚C), 1375 (C–N), 1161 (C–O), 723
(C–Cl), 562 (C–Br). 1H NMR (DMSO-d6, 400 MHz) d: 9.68
(s, 1H, Pyrimidine-H), 8.63 (s, 1H, Ar-H), 7.43 (d, 2H, Ar-
H), 7.26 (d, 2H, Ar-H), 7.15 (d, 1H, Ar-H), 7.06 (s, 1H,
NH), 3.72 (s, 3H, OCH3). MS (ESI) m/z: 556.0. Anal. calcd.
for C17H11BrCl3N3O3S2 (in %): C-36.74, H-2.00, N-7.56.
Found C-36.79, H-2.06, N-7.51.
3.2.9. Synthesis of N-[2-(5-bromo-2-chloro-pyrimidin-4-
ylsulfanyl)-4-methoxy-phenyl]-4-nitro-benzenesulfonamide (4i)
The general experimental procedure described above afforded
4i, and the product obtained from 2-(5-bromo-2-chloropyrim-
idin-4-ylthio)-4-methoxybenzenamine (2) (3.47 g, 0.01 mol)
and 2-nitro-benzenesulfonyl chloride (3i) (2.21 g, 0.01 mol).
FT-IR (KBr, cm1) m: 3276 (N–H), 2927 (C–H), 1693
(C‚N), 1464 (C‚C), 1373 (C–N), 1167 (C–O), 721 (C–Cl),
567(C–Br). 1H NMR (DMSO-d6, 400 MHz) d: 9.73 (s, 1H,
Pyrimidine-H), 8.63 (s, 1H, Ar-H), 7.53 (d, 2H, Ar-H), 7.41
(t, 3H, Ar-H), 7.21 (d, 1H, Ar-H), 7.01 (s, 1H, NH), 3.77 (s,
3H, OCH3). MS (ESI) m/z: 532.0. Anal. calcd. for
C17H12BrClN4O5S2 (in %): C-38.40, H-2.27, N-10.54. Found
C-38.47, H-2.21, N-10.59.
4. Antibacterial activity
Antibacterial activity of the synthesized compounds was deter-
mined against Gram-positive bacteria (Bacillus subtilis MTCC
121, Staphylococcus aureus MTCC 7443) and Gram-negative
bacteria (Xanthomonas campestrisMTCC 7908 and Escherichia
coliMTCC 7410) in DMF by disc diffusion method on nutrient
agar medium (Bauer et al., 1966). The sterile medium (Nutrient
AgarMedium, 15 ml) in each petri-plate was uniformly smeared
with cultures of Gram positive and Gram negative bacteria.
Sterile discs of 10 mm diameter (Hi-Media) were placed in the
petriplates, to which 50 ll (1 mg/ml i.e., 50 lg/disc) of different
synthesized compounds were added. The treatments also in-
cluded 50 ll of DMF as negative, bacteriomycin and gentamy-
cin as positive control for comparison. For each treatment,
three replicates were maintained. The plates were incubated at
37 ± 2 C for 24 h and the zone of inhibition was determined.
5. Antifungal activity
The synthesized compounds were screened for their antifungal
activity against Fusarium oxysporum MTCC 2480 in DMF by
Studies on synthesis of pyrimidine derivatives and their antimicrobial activity S489poisoned food technique (Satish et al., 2007). Potato Dextrose
Agar (PDA) medium was prepared and about 15 ml of PDA
was poured into each petriplate and allowed to solidify.
5 mm disc of seven day old culture of the test fungi was placed
at the center of the petriplate and incubated at 26 C for
7 days. After incubation the percentage inhibition was mea-
sured and three replicates were maintained for each treatment.
Nystatin was used as standard. All the synthesized compounds
were tested (at the dosage of 500 ll of the novel compounds/
petriplate, where concentration was 0.1 mg/ml) by poisoned
food technique.
6. Results and discussion
Synthesized compounds were characterized by elemental anal-
yses, FT-IR, 1H NMR and Mass spectral studies. Compounds
were puriﬁed by recrystallization method using ethanol. The
elemental analyses of data showed good agreement between
the experimentally determined values and the theoretically cal-
culated values within ±0.4%.
The absence of NH2 absorption bands in the IR spectra
conﬁrmed that the synthesized compounds were obtained.
The absorptions above 2922 cm1 in compounds, 4a–i conﬁrm
the C–H stretching vibrations, and the appearance of a med-
ium to strong absorption bands around 1700 cm1 due to a
stretching vibration of the C–N bond formation in the synthe-
sized compounds. The proton spectral data agree with respect
to the number of protons and their chemical shifts with the
proposed structures. The proton spectral data of compound
3 shows resonance at d 5.45 ppm (s, 2H, –NH2). In all the syn-
thesized compounds the above resonance peak disappeared,
which conﬁrmed the product. The synthesized compounds
were further conﬁrmed by the appearance of molecular ion
peak in mass spectra. Mass spectra of all the newly synthesized
compounds showed M+ fragmentation peak in agreement
with their molecular formula.
The investigation of antibacterial screening data revealed
that all tested compounds showed antibacterial activity against
four pathogenic bacterial strains. Among the series 4a–i, com-
pound 4e exhibited an elevated antibacterial activity against
Gram positive (zone of inhibition 29–33 mm) and Gram nega-
tive (zone of inhibition 32–33 mm) bacteria. Compounds 4b, 4h
and 4i showed good antibacterial activity against all the tested
organisms. Compounds 4a, 4c, 4d, 4f and 4g showed moderateTable 2 In vitro antibacterial and antifungal activities of 4a–i.
Compound Zone of inhibition in diameter (mm) % Inhibition
B. subtilis S. aureus X. campestris E. coli F. oxysporum
4a 28 23 28 29 69.5
4b 30 25 30 29 88.5
4c 29 23 27 29 68.6
4d 28 12 27 28 55.4
4e 33 29 32 33 96.9
4f 28 22 26 27 54.7
4g 29 22 25 27 54.3
4h 30 27 30 30 78.4
4i 31 26 29 29 76.7
Bacteriomycin – – 34 – –
Gentamycin 35 30 – 35 –
Nystatin – – – – 100inhibitory activity. The results were compared with standard
drugs bacteriomycin and gentamycin as depicted in Table 2.
The in vitro antifungal activity of the synthesized com-
pounds 4a–i was studied against Fusarium oxysporum. The re-
sults were compared with the standard drug nystatin as in
Table 2. Compound 4e showed good antifungal activity with
96.9% inhibition when compared with other compounds in
the series against F. oxysporum. The good inhibition by com-
pound 4e could be attributed to the presence of an electron
withdrawing triﬂuoromethyl group. Antimicrobial activity of
some pyrimidine derivatives has been reported (Keche et al.,
2012). Antimicrobial activity of some benzenesulfonyl deriva-
tives has been reported (Mallesha and Mohana, 2011). Com-
pounds 4b, 4h and 4i have demonstrated good antifungal
activity against F. oxysporum. Compounds 4a, 4c, 4d, 4f and
4g were found to be moderately active against tested fungal
strain. From the results it is evident that most of the com-
pounds were moderately active and few showed good activity.
Compounds 4a–i showed antimicrobial activity in the order:
4e> 4b> 4h> 4i> 4a> 4c> 4d> 4f> 4g against tested
microbial strains.
7. Conclusion
In conclusion, a series of novel 2-(5-bromo-2-chloro-pyrimi-
din-4-ylsulfanyl)-4-methoxy-phenylamine derivatives, 4a–i
was synthesized and their antimicrobial activities have been
evaluated. Compound 4e produced signiﬁcant changes in the
activity against Gram-positive and Gram-negative bacteria.
Therefore, this work presents a novel class of potent, wide-
spectrum antimicrobial activity of the compounds.
Conﬂict of interest
The authors report no conﬂicts of interest. The authors alone
are responsible for the content and writing of the paper.
Acknowledgement
One of the authors (C. Mallikarjunaswamy) is grateful to St.
Philomena’s College, Mysore, for providing laboratory facility
and thanks the University of Mysore.
References
Andriole, V.T., 1998. In Current Clinical Topics in Infectious Diseases.
Blackwell Sciences, p. 19.
Appelbaum, P.C., Hunter, P.A., 2000. Int. J. Antimicrob. Agents. 16, 5.
Ball, P., 2000. J. Antimicrob. Chemother. 46, 17.
Bauer, A.W., Kirby, W.M., Sherris, J.C., Turck, M., 1966. Am. J. Clin.
Pathol. 45, 493.
Brown, D.J., 1962. The Chemistry of Heterocyclic Compounds.
Interscience, New York, p. 16.
Chang, S., Yin, S.L., Wang, J., Jing, Y.K., Dong, J.H., 2009.
Molecules 14, 4166.
Frere, J.M., 1995. Mol. Microbiol. 16, 385.
Ghoneim, K.M., Youssef, R., 1986. J. Indian Chem. Soc. 53, 914.
Karale, B.K., Gill, C.H., 2002. Indian J. Chem. 41B, 1957.
Keche, A.P., Hatnapure, G.D., Tale, R.H., Rodge, A.H., Birajdar,
S.S., Kamble, V.M., 2012. Bioorg. Med. Chem. Lett. 22, 3445.
Kenner, G.W., Todd, A., 1957. Heterocyclic Compounds. Wiley, New
York, p. 6.
S490 C. Mallikarjunaswamy et al.Koca, M., Servi, S., Kirilmis, C., Ahmedzade, M., Kazaz, C., Ozbek,
B., Otuk, G., 2005. Eur. J. Med. Chem. 40, 1351.
Mallesha, L., Mohana, K.N., 2011. Eur. J. Chem. 2, 193.
Reddy, V.M., Sarma Rama, G.V.S., 1993. Indian J. Heterocycl. Chem.
3, 111.Satish, S., Mohana, D.C., Raghavendra, M.P., Raveesha, K.A., 2007.
J. Agric. Technol. 3, 109.
Shingare, M.S., Karale, B.K., Gill, C.H., Gange, K.N., Bachute, M.T.,
1999. Indian J. Heterocycl. Chem. 9, 153.
